Evidence-based decision making in healthcare in Central Eastern Europe

References

• The pharmacoeconomics section of the pharmaceutical Association of Serbia. Website of Farmako Ekonomija. Available from: www.farmakoekonomija.org/?content=iv&lang=EN [Last accessed 22 May 2014]
   Google Scholar
• IHPA. Website of the Australian Independent Hospital Pricing Authority (IHPA). Available from: www.ihpa.gov.au/internet/ihpa/publishing.nsf [Last accessed 21 May 2014]
   Google Scholar
• Society of Nephrology, Dialysis and Kidney Transplantation in Bosnia and Herzegovina. The Renal Register for Bosnia and Herzegovina. Available from: www.undt.ba/en/the-renal-register [Last accessed 21 May 2014]
   Google Scholar
• Gartner. IT Glossary - Big Data 2012. Available from: www.gartner.com/it-glossary/big-data/ [Last accessed 21 May 2014]
   Google Scholar
• Zhao S, Nishimura T, Chen Y, et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med 2013;5(206):206ra140
   PubMed Web of Science ®Google Scholar
• Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event simulation a report of the ISPOR-SMDM modeling good research practices task force–4. Med Decis Making 2012;32(5):701-11
   PubMed Web of Science ®Google Scholar
• Vogler S, Schmickl B. Rationale Arzneimitteltherapie in Europa. Österreichisches Bundesinstitut für Gesundheitswesen; Vienna: 2010. p. 1-45
   Google Scholar
• Kusel J, Wong GK. NI2 the use of off-label comparators in nice appraisals – an indirect endorsement? Value Health 2012;15(7):A278
   Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet 2013;382(9900):1258-67
   PubMed Web of Science ®Google Scholar
• News Medical. IVAN study: Lucentis and Avastin effective in treating wet AMD. Available from: http://www.news-medical.net/news/20130720/IVAN-study-Lucentis-and-Avastin-effective-in-treating-wet-AMD.aspx [Last accessed 21 May 2014]
   Google Scholar
• Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: justum Pretium – the just price. J Clin Oncol 2013;31(28):3600-4
   PubMed Web of Science ®Google Scholar
• Prescrire Int. New drugs and indications in 2012 Sluggish progress, timid measures to protect patients. Prescrire Int 2013;22(137)):105-7
   PubMedGoogle Scholar
• Malmström RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 2013;4:39
   PubMed Web of Science ®Google Scholar
• Godman B, Paterson K, Malmström RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res 2012;12(4)):439-41
   PubMedGoogle Scholar
• Woerkom M van, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res 2012;1(6):527-38
   PubMedGoogle Scholar
• Garuoliene K, Godman B, Gulbinovič J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res 2011;11(3)):343-9
   PubMedGoogle Scholar
• Markovic-Pekovic V, Skrbić R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Pharmacoecon Outcomes Res 2012;12(5):661-71
   PubMed Web of Science ®Google Scholar
• Gustafsson LL, Wettermark B, Godman B, et al. The “wise list”- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108(4):224-33
   PubMed Web of Science ®Google Scholar
• GKV-Spitzenverband. AMNOG - evaluation of new pharmaceutical. Available from: www.gkv-spitzenverband.de/english/statutory_health_insurance/amnog___evaluation_of_new_pharmaceutical/amnog___evaluation_of_new_pharmaceutical_1.jsp [Last accessed 21 May 2014]
   Google Scholar
• Moga C, Corabian P, Juzwishin D, et al. Developing health technology assessment in Romania. EuroHealth 2003;9:30-4
   Google Scholar
• Corabian P, Hailey D, Harstall C, et al. Mentoring a developing health technology assessment initiative in Romania: an example for countries with limited experience of assessing health technology. Int J Technol Assess Health Care 2005;21(4):522-5
   PubMedGoogle Scholar
• Ruiz F, Lopert R, Chalkidou K. Technical assistance in reviewing the content and listing processes for the romanian basic package of health services and technologies. Final report and Recommendations: Next Steps. NICE International. 2012
   Google Scholar
• Gesundheit Österreich. Website of the WHO collaborating centre for pharmaceutical pricing and reimbursement policies. Available from: http://whocc.goeg.at/Networks/Organisation [Last accessed 21 May 2014]
   Google Scholar
• Piperska Group. Website of the Piperska Group - Rational Prescribing. Available from: www.piperska.org/ [Last accessed 21 May 2014]
   Google Scholar
• Lichtenberg FR. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000-2009. National Bureau of Economic Research. Report No.: 18235. Available from www.nber.org/papers/w18235 [Last accessed July 2012]
   Google Scholar
• Baker D, Fugh-Berman A. Do new drugs increase life expectancy? A critique of a Manhattan Institute paper. J Gen Intern Med 2009;24(5):678-82
   PubMedGoogle Scholar
• Barbieri M, Drummond M, Willke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health J Int Soc Pharmacoeconomics Outcomes Res 2005;8(1):10-23
   PubMed Web of Science ®Google Scholar
• Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess Winch Engl 2004;8(49)):iii-v.1-192
   Google Scholar
• O’Brien BJ. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Manag Care 1997;3 Suppl:S33-9
   Google Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 2009;12(4)):409-18
   PubMedGoogle Scholar